

Research



Decreased number of hospitalized children with severe acute lower respiratory infection after introduction of the pneumococcal conjugate vaccine in the Eastern Democratic Republic of the Congo

Archippe Muhandule Birindwa, Jeanniere Tumusifu Manegabe, Aline Mindja, Rickard Nordén, Rune Andersson, Susann Skovbjerg

Corresponding author: Archippe Muhandule Birindwa, Panzi Hospital, Bukavu, Democratic Republic of Congo. birindwaarchippe@gmail.com

Received: 01 Apr 2020 - **Accepted:** 07 Apr 2020 - **Published:** 03 Nov 2020

Keywords: Acute lower respiratory infections, case fatality, 13-valent pneumococcal conjugate vaccine, Democratic Republic of the Congo

Copyright: Archippe Muhandule Birindwa et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Archippe Muhandule Birindwa et al. Decreased number of hospitalized children with severe acute lower respiratory infection after introduction of the pneumococcal conjugate vaccine in the Eastern Democratic Republic of the Congo. Pan African Medical Journal. 2020;37(211). 10.11604/pamj.2020.37.211.22589

Available online at: <https://www.panafrican-med-journal.com/content/article/37/211/full>

Decreased number of hospitalized children with severe acute lower respiratory infection after introduction of the pneumococcal conjugate vaccine in the Eastern Democratic Republic of the Congo

Archippe Muhandule Birindwa^{1,2,3,&}, Jeanniere Tumusifu Manegabe², Aline Mindja², Rickard Nordén^{1,4}, Rune Andersson^{1,4,5}, Susann Skovbjerg^{1,4,5}

¹Department of Infectious Disease, Institute of Biomedicine, University of Gothenburg,

Gothenburg, Sweden, ²Panzi Hospital, Bukavu, Democratic Republic of Congo, ³Université Évangélique en Afrique, Bukavu, Democratic Republic of Congo, ⁴Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden, ⁵Centre for Antibiotic Resistance Research (CARE), Gothenburg University, Gothenburg, Sweden

&Corresponding author

Archippe Muhandule Birindwa, Panzi Hospital, Bukavu, Democratic Republic of Congo

Abstract

Introduction: acute lower respiratory infections (ALRI) are a leading killer of children under five worldwide including the Democratic Republic of the Congo (DR Congo). We aimed to determine the morbidity and case fatality rate due to ALRI before and after introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) in DR Congo 2013. **Methods:** data were collected from medical records of children with a diagnosis of ALRI, aged from 2 to 59 months, treated at four hospitals in the Eastern DR Congo. Two study periods were defined; from 2010 to 2012 (before introduction of PCV13) and from 2014 to 2015 (after PCV13 introduction). **Results:** out of 21,478 children admitted to the hospitals during 2010-2015, 2,007 were treated for ALRI. The case fatality rate among these children was 4.9%. Death was significantly and independently associated with malnutrition, severe ALRI, congenital disease and symptoms of fatigue. Among the ALRI hospitalised children severe ALRI decreased from 31% per year to 18% per year after vaccine introduction ($p = 0.0002$) while the fatality rate remained unchanged between the two study periods. Following introduction of PCV13, 63% of the children diagnosed with ALRI were treated with ampicillin combined with gentamicin while 33% received ceftriaxone and gentamicin. **Conclusion:** three years after PCV13 introduction in the Eastern part of the DR Congo, we found a reduced risk of severe ALRI among children below five years. Broad-spectrum antibiotics were frequently used for the treatment of ALRI in the absence of any microbiological diagnostic support.

Introduction

Acute lower respiratory infections (ALRI) are a leading cause of mortality and morbidity in children under five years, particularly in low- and middle-income countries [1-3]. In 2016, there were over 68 million episodes of ALRI among children younger than 5 years worldwide; this was equivalent to 0.11 cases per child-year, and more

than 5 million children were hospitalised due to the infection [2]. In the Democratic Republic of the Congo (DR Congo), ALRI caused 20% of the deaths among children between 1 and 59 months in 2017 and the rate of deaths due to ALRI was 9.4 per 1,000 live births in the same age group [4]. Approximately 40% only of the children below five years with ALRI or suspected pneumonia in the DR Congo were treated by a qualified healthcare provider while the remaining children were taken care of by non-appropriate providers (e.g. private pharmacies, traditional practitioners, relatives or other services, such as shops) [5, 6].

In 2013, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced into the general vaccination program for children below one year of age in DR Congo. The vaccine was given at 6, 10 and 14 weeks of age without any catch-up campaign. In 2016, the PCV was estimated to prevent 52,000 ALRI-related deaths in children below 5 years worldwide [2]. Several published studies have documented a reduction in all manifestations of pneumococcal disease following the routine use of PCV13 or PCV10 in low- and middle-income countries [7-11]. Pneumonia, the most severe manifestation of pneumococcal-caused ALRI, is classified by the World Health Organisation (WHO) as rapid breathing and/or chest indrawings in a child between 2 and 59 months while severe pneumonia is defined as pneumonia with the addition of any general danger signs, (i.e. inability to drink, persistent vomiting, convulsions, lethargy or unconsciousness, stridor in a calm child or severe malnutrition) [12].

According to the WHO pneumonia management guidelines, children between 2 and 59 months with pneumonia should be treated with amoxicillin, while those with severe pneumonia should be given the parenteral ampicillin (or penicillin) plus the gentamicin combination for at least five days as a first-line treatment [12]. The WHO recommendations also state that children failing this first-line treatment should be offered a referral to a facility with access to appropriate second-line treatment with ceftriaxone [12]. In this study, we

recorded the morbidity and fatality rates in children requiring hospital care for ALRI both before and after start of the PVC13 immunization program in DR Congo. We also assessed the antibiotic treatments used for these children. We chose to include all children with ALRI (i.e. not only pneumonia cases) because, in many cases, the patient records were not detailed enough to either exclude or confirm pneumonia according to the WHO classification. In addition, the hospital diagnoses were only based on clinical assessment by the doctors, due to limited access to X-ray and other diagnostic tools.

Methods

Data collection

From January 2010 to December 2015 a total of 21,552 children aged from 2 to 59 months treated at four hospitals in the South-Kivu province in the Eastern part of the DR Congo were eligible for inclusion in the study. Of these, 74 children were excluded, 47 due to missing information and 27 due to patients leaving before end of treatment, mainly because they were not able to pay for the treatment costs. Of the remaining 21,478 children data were collected for 2,007 children identified with a diagnosis of ALRI; the data was taken from medical records hand-written by physicians. For comparison between the periods both before and after introduction of PCV13 the data were divided into the following two study groups; 8,283 hospitalized children during 2010-2012 (i.e. before introduction of PCV13) and 9,713 during 2014-2015 (i.e. after PCV13 introduction). During 2013 (the year of PCV13 vaccine introduction) data from 3,482 cases were not included in the comparison between the pre- and post-vaccine period. However, these were included in the overall description of ALRI, case fatalities and antibiotic treatment assessments.

Study areas

The study was performed at two general referral hospitals, Panzi Hospital and Ciriri Hospital and two

district hospitals, Miti Murhesa and Nyantede. Panzi Hospital, located in Bukavu town, is a teaching hospital that served a population of 453,000 inhabitants including 86,000 (19%) children below 5 years at the time of the study. The general referral hospital, Ciriri, located in the suburban area of Bukavu, served a population of 337,000 inhabitants including 71,000 (21%) children below five years. The other two district hospitals were located in rural areas; the Miti Murhesa district hospital served a population of 231,000 inhabitants including 52,000 (23%) children below 5 years, and the Nyantede Hospital, 132,000 inhabitants including 29,000 (22%) children [6].

Definitions

Cases were considered as ALRI if the medical records contained any of the following discharge diagnoses: pneumonia, atypical pneumonia, bronchopneumonia, bronchitis, bronchiolitis, rhino-bronchitis, rhino-bronchiolitis, rhino-pharyngo-bronchitis, bronchopneumonia or any combination of these, with or without association with upper respiratory tract infection as assessed by the physician at the admission or at discharge from the hospital. A case was considered as severe ALRI if the medical records had a discharge diagnosis of severe or very severe pneumonia, or pneumonia with the addition of any general danger signs (not able to drink, persistent vomiting, convulsions, lethargy or unconsciousness, stridor in a calm child or severe malnutrition). The International Statistical Classification of Diseases and Related Health Problems was not used in the DR Congo and was therefore not applicable. Data were collected on age, sex, admission dates, duration of hospital care and outcome (i.e. death, complications, improvement, and cure). Recorded symptoms included the following: rapid breathing (defined as >60 respiratory rates (RR) per minute in children below 3 months, > 50 RR/min in children 3-12 months and > 40 RR/min in children >12-59 months), breathing difficulty, fever, cough or recent history of cough, weakness or fatigue, diarrhoea, vomiting, chest indrawings. Results from

lung auscultations were recorded; the presence of crackles and/or rhonchi were considered as abnormal auscultation. The data were also collected on underlying conditions including malnutrition, HIV, sickle cell disease, cerebral palsy, post neonatal anoxia or congenital diseases and also the use of antibiotics and oxygen. X-ray was not used for confirming the diagnosis of pneumonia as only two of the selected hospitals (Panzi and Ciriri) had the required facilities.

Statistical analysis

Descriptive analysis was performed by SPSS package (version 23.0) for logistic regression to analyse relationship between death and socio-demographic factors (age, sex, year of hospitalisation), duration of hospital stay, antibiotic treatments and underlying conditions. Prevalence rates with a 95% confidence interval (CI) were calculated to compare the morbidity and case fatality rates both before and after introduction of PCV13. Associations between categorical variables were analysed using the Pearson Chi-square or Fisher's exact test, where appropriate. A p-value < 0.05 was considered statistically significant. Potential variables associated with the impact of PCV13 on pneumococcal pneumonia were assessed by odd ratios (OR) with a 95% CI.

Ethics approval and consent to participate

The study was approved by the Commission Institutionnelle d'Éthique (CIE) of the Université Catholique de Bukavu (N/Ref: (UCB/CIE/NC/06/2015) in accordance with existing ethical guidelines in DR Congo. The four Directors of the included hospitals in the study were informed and approved the study.

Availability of data and material

The datasets used and analysed during the current study are available from the corresponding author upon reasonable request.

Funding

This study was supported by funds at the Sahlgrenska Academy, University of Gothenburg. The funding body had no role in the design of the study, the collection, analysis or interpretation of data, nor in writing of the manuscript.

Results

Characteristics of the study population

A total of 2,007 (9.4%) children aged from 2 to 59 months (median of 11 months) were treated for ALRI out of 21,478 children hospitalised in the paediatric wards during 2010-2015 at four different hospitals in the south-Kivu province of Eastern DR Congo. Of these ALRI cases, 542 (27.0%) children had severe ALRI, while the remaining 1,465 (73.0%) had a diagnosis defined as non-severe ALRI (Table 1). Clinical characteristics and socio-demographic data for all children with ALRI are presented in Table 1 and Table 2. Hospitalisation due to ALRI peaked in January (n = 321, 16.0%) and December (n = 271, 13.5%) (Figure 1). The ALRI population mortality rate was estimated at 0.08 children per 100,000 inhabitants per year. The overall fatality rate in the hospitalised children with ALRI was 4.9%, and the highest fatality rate (17.5%) occurred in October (Figure 1). All but one child presented with symptoms of cough or had a history of acute cough, abnormal auscultation upon physical examination and fever (Table 1). Fatigue or weakness was found in 74.1% of ALRI cases and rapid breathing or breathing difficulty in 43.2% (Table 1). Pleural effusion was the most common complication affecting 1.0% of cases. Half of the cases (50.4%) were hospitalised for three to seven days (Table 1).

Morbidity and case fatality rate due to ALRI both before and after start of PVC13

Out of the 8,283 children between 2 and 59 months treated at any of the hospitals during the first study period (2010-2012), 1,009 cases (12.2% of all admissions) were treated for ALRI while 693/9,713

cases (7.1% of all admissions) were treated for ALRI during the period after the introduction of PCV13 (2014-2015) ($p < 0.0001$). Severe ALRI for hospitalised children decreased from 103/336 (31%) per year to 64/347 (18%) per year after vaccine introduction ($p = 0.0002$) while the total average number of ALRI cases remained unchanged between the two periods (Table 3). In children below 24 months of age the proportion of all ALRI cases decreased after PCV13 introduction, but this remained unchanged in the older children (Table 3). The proportion of cases with rapid breathing or breathing difficulty also decreased after introduction of the vaccination from 45.8% to 35.4%; ($p = 0.016$) while the case fatality rate remained similar between the two study periods (Table 2).

Fatality risk factors

Out of the 2,007 children treated for ALRI during the whole 6-year period from 2010 to 2015, 99 (4.9%) died due to the disease. The case fatality rate was significantly associated with severe ALRI (OR 28.58; 95% CI 14.74-55.42; $p < 0.0001$) (Table 4). Children hospitalised for ALRI and also had malnutrition or a congenital disease as underlying conditions, had a 9.8 and 12.4 times greater risk of dying, respectively (Table 4). The case fatality rate was 3.9 times higher in children with symptoms of fatigue (Table 4).

Antibiotic treatments of pneumonia

Among the children with non-severe ALRI, 1175/1465 (80.2%) patients were treated with the ampicillin and gentamicin combination, (i.e. the treatment recommended by the WHO for severe pneumonia, while the second-line treatment ceftriaxone combined with gentamicin was used for 254/1465 (17.3%) patients. Among the children with severe ALRI, 344/542 (63.5%) were treated with the ceftriaxone and gentamicin combination while 138/542 (25.5%) were treated with the ampicillin and gentamicin combination. After the introduction of PCV13 vaccine, the use of ceftriaxone combined with gentamicin increased

significantly whereas there was a slight (non-significant) decrease for the ampicillin and gentamicin combination (Table 3). During the 6-year study period, there was considerable use of antibiotics not recommended for pneumonia. This included 70 (3.5%) patients treated with ciprofloxacin, 18 of whom were non-severe ALRI cases. In addition, 26 (1.3%) were treated with chloramphenicol, 18 of whom were children with non-severe ALRI (Table 1).

Discussion

The proportion of children aged 2-59 months admitted to hospitals in the Eastern part of the DR Congo with acute lower respiratory infections (ALRI) was 9.4% out of a total of 21,478 all-cause hospitalisations during the study period 2010-2015. This proportion is lower compared to other low-income countries, and could be due to less accessibility to hospital care in the Eastern part of the DR Congo [13, 14]. Differences between studies may also depend on variations in the definitions of ALRI. In this study, the ALRI diagnoses were defined by more than ten different physicians from various different medical backgrounds with limited access to diagnostic tools, including X-ray and microbiological diagnostic tools. Due to the retrospective study design we did not consider the WHO classification of pneumonia to be applicable, rather we chose to use the broader terms, ALRI and severe ALRI instead of pneumonia and severe pneumonia, respectively.

Most cases accrued in December and January, while most ALRI-related deaths occurred in October. The rainy season starts in September and ends in June leading to heavy rainfalls in the region, often accompanied by viral ALRI outbreaks [15-17]. Viral infections can cause severe acute respiratory infections in children. They may also be associated with secondary bacterial infections, in particular with pneumococcal bacteria [18]. We found an ALRI-related hospital mortality rate of 0.08 children per 1,000 live births while in 2016, the overall child mortality rate for DR Congo was 94.3 deaths per 1,000 live births in children below five years of

age [19]; the figures were as high as 125 deaths per 1,000 live births in the South-Kivu province of DR Congo in 2014 [6]. This indicates a low mortality rate in children treated in hospitals but that only few of the sick children actually reach the hospitals. Up to 80% of deaths in severe respiratory infections may occur outside hospitals [14], indicating the need for a qualified primary healthcare system, in remote as well as urban areas.

The case fatality rate of 4.9% in our study was lower compared to studies from Malawi and Nigeria, both showing rates of about 10% [20, 21], and was much lower than the rates reported for hospitalised children in Mauritania (18%) [22]. Conversely, lower case fatality rates were reported in South Africa (2%) [23]. In the present study, hospitalisation due to severe ALRI conferred 28 times higher risk for fatal outcome compared to non-severe ALRI. Similar results were found in Malawi, Nigeria and in Bangladesh, where risk of death was greatest in children between 2 and 11 months and those with very severe pneumonia [20, 21, 24]. This might be explained by the quality of healthcare standards and organisation, the accessibility and the absence of clinical guidelines [25].

We further identified malnutrition and congenital disease as underlying conditions increasing the risk of fatal outcome in ALRI. Malnutrition is an important co-factor for severe infections; it is associated with immune-deficiency and respiratory muscle atrophy and can triple the mortality risk of pneumonia [26, 27]. Malnutrition has previously been associated with death in childhood pneumonia in several countries, including the Central African Republic, India, Brazil and Bangladesh [24, 28-30]. Diminished immune function via reduced production and/or diminished function of the immune system cellular components is an explanation for the increased incidence and severity of infections in malnourished children [31]. We further found the symptom of fatigue to be an independent risk factor for death. Weakness or fatigue can be found in most severely ill children; however, the

evaluation of this symptom can differ from one physician to another, especially if no standardized definition exists.

Our results support the evidence that PCV13 reduces the frequency of hospital care due to severe ALRI [8, 32-34]. The proportion of severe ALRI cases decreased from 31% on average per year to 18% on average per year after introduction of PCV13. In addition, the proportion of all ALRI cases decreased in children below 24 months of age but remained unchanged in older children. Most of the children older than 3 years in the region had not received PCV13 at the time of the study. PCV13 impact studies in countries supported by the Vaccine Alliance GAVI (Burkina Faso, Gambia, Lao PDR, Mongolia, Malawi, Papua New Guinea, Rwanda and Togo) have demonstrated that, two years after PCV13 introduction, pneumonia hospitalisations were significantly reduced by 33% in children below 12 months of age and by 26% in children between 12 and 23 months of age [7, 35]. At the Children's Hospital in Montevideo, Uruguay, the hospitalisation rates for community-acquired pneumonia and pneumococcal pneumonia decreased significantly in all children by 56% and 43%, respectively, both between the pre-vaccine years (2005-2007) and during the year after vaccination introduction (2009) [36]. Furthermore, in Malawi, a considerable decrease in severe pneumonia cases and death was shown in children after PCV13 introduction [37]. In this study, the relatively low case fatality rate in children admitted to hospital for ALRI remained unchanged both before and after PCV13 introduction. Since many critically-ill Congolese children never reach the hospitals a community-based study could hypothetically have arrived at a different conclusion on the impact of PCV13.

We found that the use of ceftriaxone in combination with gentamicin for ALRI was high; also, there was a tendency towards increased use after introduction of PCV13 vaccine while there was a tendency towards decreased use of ampicillin in combination with gentamicin. The WHO guidelines recommend the use of the ceftriaxone and

gentamicin combination for pneumonia cases showing no improvement on treatment with the ampicillin and gentamicin combination [12]. It was not possible to evaluate the rationale for antibiotic use since no bacteriologic cultures were performed in our study cohort. Nevertheless, our data revealed the use of ciprofloxacin for 70 (3.8%) patients and chloramphenicol for 26 (1.4%) patients despite this not being recommended for the treatment of pneumonia. Moreover, we have recently shown a high level of resistance to commonly-used antibiotics in the region (i.e. penicillin, co-trimoxazole and ceftriaxone) for pneumococci carried in the nasopharynx of healthy children [38]. This highlights the need for a more rational use of antibiotics in the region.

Conclusion

Three years after PCV13 introduction in the Eastern part of the DR Congo, we found a decrease in severe ALRI in children below five years. Children with severe ALRI, or those with underlying conditions including malnutrition or congenital disease had a higher risk of death compared to those hospitalised for non-severe ALRI or those without any underlying conditions. We highlight the inappropriate use of antibiotics, such as chloramphenicol and ciprofloxacin for ALRI especially in the absence of any diagnostic microbiological support.

What is known about this topic

- *PCV13 have been shown to reduce severe childhood respiratory infections in other parts of Sub-Saharan Africa;*
- *Ampicillin combined with gentamicin is the recommended first line treatment of severe pneumonia.*

What this study adds

- *We found a significant reduction of children hospitalized due to severe acute lower respiratory infections (ALRI) after introduction of PCV13 in the infant vaccination program in the Eastern part of DR Congo;*

- *That risk factors such as malnutrition, congenital diseases and severe ALRI were associated with case fatality in hospitalized children with ALRI in the region;*
- *There is an inappropriate use of antibiotics for ALRI, such as chloramphenicol and ciprofloxacin, especially in the absence of any microbiological diagnostic support.*

Competing interests

The authors declare no competing interests.

Authors' contributions

SS, RA and RN designed and supervised the study. AMB, JM, and AM collected data from all medical records of admitted patients. AMB analysed the data in close communication with SS, RA and RN under the orientation of statisticians at the University of Gothenburg. AMB was mainly responsible for writing the manuscript, which was critically revised by SS, RA, and RN. All authors read and approved the final manuscript.

Acknowledgments

Acknowledgments to the Gothenburg University Research Fund for starting up research in global health. Our sincere appreciation is also due to all the staff at Panzi Hospital, Ciriri Hospital, Nyatende Hospital and Mitimurhesa Hospital for their co-operation and collaboration in this study. We thank the staff of the different implicated hospitals in this study.

Tables and figure

Table 1: socio-demographic data and clinical characteristics of the children treated at the hospitals due to acute lower respiratory infection during 2010-2015

Table 2: socio-demographic characteristics of hospitalized children with ALRI during 2010-2015

Table 3: morbidity and case fatalities of acute lower respiratory infections (ALRI) by year mean (annual

average) both before (2010-2012) and after (2014-2015) start of PVC13 immunization

Table 4: identified fatality risk factors among hospitalised children with acute lower respiratory infections (ALRI) (n=2,007) during the period between 2010-2015

Figure 1: frequencies of acute lower respiratory infections (ALRIs) and fatal outcome by month in children 2-59 months of age treated due to ALRI at four different hospitals in the east of DR Congo between 2010 and 2015

References

1. Naghavi M, Abajobir AA, Abbafati C, Abbas KM, Abd-Allah F, Abera SF *et al.* Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet*. 2017 Sep 16;390(10100): 1151-1210. **PubMed** | **Google Scholar**
2. Collaborators GLRI. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Infectious diseases*. 2018 Nov;18(11): 1191-1210. **PubMed** | **Google Scholar**
3. Seidu A-A, Dickson KS, Ahinkorah BO, Amu H, Darteh EKM, Kumi-Kyereme A. Prevalence and determinants of acute lower respiratory infections among children under-five years in sub-Saharan Africa: evidence from demographic and health surveys. *SSM-population health*. 2019 Jul 4;8: 100443. **PubMed** | **Google Scholar**
4. WHO. Estimates of child cause of death, Acute Respiratory Infection 2018. 2018. Accessed on 26th January, 2020.
5. Noordam AC, Carvajal-Velez L, Sharkey AB, Young M, Cals JW. Care seeking behaviour for children with suspected pneumonia in countries in sub-Saharan Africa with high pneumonia mortality. *PLoS One*. 2015 Feb 23;10(2): e0117919 eCollection 2015. **PubMed** | **Google Scholar**
6. Deuxième enquête démographique et de santé (EDS-RDC II 2013-2014): République démocratique du Congo. Septembre 2014. **Google Scholar**
7. Rodgers GL, Klugman KP. Surveillance of the impact of pneumococcal conjugate vaccines in developing countries. *Human vaccines and immunotherapeutics*. 2016 Feb;12(2): 417-420. **Google Scholar**
8. Bustreo F, Okwo-Bele J, Kamara L. World Health Organization perspectives on the contribution of the Global Alliance for Vaccines and Immunization on reducing child mortality. *Archives of disease in childhood*. 2015 Feb;100 Suppl 1: S34-7. **PubMed** | **Google Scholar**
9. Becker-Dreps S, Amaya E, Liu L, Moreno G, Rocha J, Briceño R *et al.* Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. *The Pediatric infectious disease journal*. 2014 Jun;33(6): 637-42. **PubMed** | **Google Scholar**
10. Flasche BA, McIntyre P, Younkin J, Sigauque B, O'Brien K, Cherian T. WHO technical expert consultation report on optimization of PCV impact: review of evidence and programmatic considerations to inform policy. WHO HQ Salle C, June 12-13, 2017. **Google Scholar**
11. Silaba M, Ooko M, Bottomley C, Sande J, Benamore R, Park K *et al.* Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis. *The Lancet Global Health*. 2019 Mar;7(3): e337-e346. **PubMed** | **Google Scholar**

12. Organization WH. Revised WHO classification and treatment of childhood pneumonia at health facilities. Geneva: World Health Organization. 2014: 6-14.
13. Niederman MS, Krilov LR. Acute lower respiratory infections in developing countries. *The Lancet*. 2013 Apr 20;381(9875): 1341-1342. **PubMed** | **Google Scholar**
14. Nair H, Simões EAF, Rudan I, Gessner BD, Azziz-Baumgartner E, Zhang JSF *et al*. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. *The Lancet*. 2013 Apr 20;381(9875): 1380-1390 Epub 2013 Jan 29. **PubMed** | **Google Scholar**
15. Ngombe LK, Kameya N, Malingo AA, Kayomb NK, Nday D, Numbi L. Acute respiratory infection and nutritional status in children 0-5 years: case of university clinics of Lubumbashi, Democratic Republic of Congo. *The Pan African medical journal*. 2014 Dec 18;19: 393. **PubMed** | **Google Scholar**
16. Bakonde B, Tatagan K, Kessie K, Kafechina A, Assimadi K, Paupe J *et al*. Epidémiologie hospitalière des infections respiratoires aiguës (ira) basses chez le nourrisson et l'enfant togolais. *Médecine d'Afrique Noire*. 1998;45(7): 435-9. **Google Scholar**
17. Wen S, Yu M, Zheng G, Lv F, Chen X, Lin L *et al*. Changes in the etiology of viral lower respiratory tract infections in hospitalized children in Wenzhou, China: 2008-20 *Journal of Medical Virology*. 2020 Aug;92(8): 982-987 Epub 2020 Jan 17. **PubMed** | **Google Scholar**
18. Madhi SA, Klugman KP, Group TVT. A role for *Streptococcus pneumoniae* in virus-associated pneumonia. *Nature medicine*. 2004 Aug;10(8): 811-3 Epub 2004 Jul 11. **PubMed** | **Google Scholar**
19. Hug L, Sharrow D, You D. Levels & trends in child mortality: report 2017. Estimates developed by the UN Inter-agency Group for Child Mortality Estimation. 2017. **PubMed** | **Google Scholar**
20. Enarson PM, Gie RP, Mwansambo CC, Maganga ER, Lombard CJ, Enarson DA *et al*. Reducing deaths from severe pneumonia in children in Malawi by improving delivery of pneumonia case management. *PloS one*. 2014 Jul 22;9(7): e102955 eCollection 2014. **PubMed** | **Google Scholar**
21. Bokade CM, Madhura AD, Bagul AS, Thakre SB. Predictors of mortality in children due to severe and very severe pneumonia. *Nigerian medical journal: journal of the Nigeria Medical Association*. Jul-Aug 2015;56(4): 287-91. **PubMed** | **Google Scholar**
22. Ahmed M, Weddih A, Benhafid M, Bollahi M, Sidatt M, Makhalla K *et al*. Hospitalizations and deaths associated with diarrhea and respiratory diseases among children aged 0-5 years in a Referral Hospital of Mauritania. *Tropical medicine and infectious disease*. 2018 Sep; 3(3): 103. **PubMed** | **Google Scholar**
23. Cohen C, Walaza S, Moyes J, Groome M, Tempia S, Pretorius M *et al*. Epidemiology of viral-associated acute lower respiratory tract infection among children < 5 years of age in a high HIV prevalence setting, South Africa, 2009-2012. *The Pediatric infectious disease journal*. 2015 Jan;34(1): 66-72. **PubMed** | **Google Scholar**
24. Saha S, Hasan M, Kim L, Farrar JL, Hossain B, Islam M *et al*. Epidemiology and risk factors for pneumonia severity and mortality in Bangladeshi children < 5 years of age before 10-valent pneumococcal conjugate vaccine introduction. *BMC public health*. 2016 Dec 7;16(1): 1233. **PubMed** | **Google Scholar**
25. Nguyen PT, Tran HT, Fitzgerald DA, Tran TS, Graham SM, Marais BJ. Characterisation of children hospitalised with pneumonia in central Vietnam: a prospective study. *European Respiratory Journal*. 2019 Jul 11;54(1): 1802256. **PubMed** | **Google Scholar**
26. Black RE, Allen LH, Bhutta ZA, Caulfield LE, De Onis M, Ezzati M *et al*. Maternal and child undernutrition: global and regional exposures and health consequences. *The lancet*. 2008 Jan 19;371(9608): 243-60. **PubMed** | **Google Scholar**

27. Alcoba G, Kerac M, Breyse S, Salpeteur C, Galetto-Lacour A, Briend A *et al.* Do children with uncomplicated severe acute malnutrition need antibiotics? A systematic review and meta-analysis. *PLoS One*. 2013;8(1): e53184. **PubMed | Google Scholar**
28. Demers A-m, Morency P, Mberyo-Yaah F, Jaffar S, Blais C, SomsÉ P *et al.* Risk factors for mortality among children hospitalized because of acute respiratory infections in Bangui, Central African Republic. *The Pediatric infectious disease journal*. 2000 May;19(5): 424-32. **PubMed | Google Scholar**
29. Ferreira S, Sant'Anna CC, Maria de Fátima B, Santos MAR, Cunha AJLA. Lethality by pneumonia and factors associated to death. *Jornal de pediatria*. Jan-Feb 2014;90(1): 92-7.. **PubMed | Google Scholar**
30. Ramachandran P, Nedunchelian K, Vengatesan A, Suresh S. Risk factors for mortality in community-acquired pneumonia among children aged 1-59 months admitted in a referral hospital. *Indian pediatrics*. 2012;49(11): 889-95. **Google Scholar**
31. Rodríguez L, Cervantes E, Ortiz R. Malnutrition and gastrointestinal and respiratory infections in children: a public health problem. *International journal of environmental research and public health*. 2011 Apr;8(4): 1174-205. **PubMed | Google Scholar**
32. Zar H, Madhi S, Aston S, Gordon S. Pneumonia in low and middle income countries: progress and challenges. *Thorax*. 2013 Nov;68(11): 1052-6. **PubMed | Google Scholar**
33. Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. *The Lancet Respiratory medicine*. 2014 May;2(5): 387-94. **PubMed | Google Scholar**
34. Fortunato F, Martinelli D, Cappelli MG, Cozza V, Prato R. Impact of pneumococcal conjugate universal routine vaccination on pneumococcal disease in Italian children. *Journal of immunology research*. 2015;2015: 206757. **PubMed | Google Scholar**
35. Levy C, Cohen R. Tackling childhood pneumonia in Africa: a dream that becomes reality. *The Lancet Global Health*. 2019 Mar;7(3): e288-e289. **PubMed | Google Scholar**
36. Hortal M, Estevan M, Meny M, Iraola I, Laurani H. Impact of pneumococcal conjugate vaccines on the incidence of pneumonia in hospitalized children after five years of its introduction in Uruguay. *PLoS One*. 2014 Jun 6;9(6): e98567. **PubMed | Google Scholar**
37. McCollum ED, Nambiar B, Deula R, Zadutsa B, Bondo A, King C *et al.* Impact of the 13-valent pneumococcal conjugate vaccine on clinical and hypoxemic childhood pneumonia over three years in central Malawi: an observational study. *PloS one*. 2017 Jan 4;12(1): e0168209. **PubMed | Google Scholar**
38. Birindwa AM, Emgård M, Nordén R, Samuelsson E, Geravandi S, Gonzales-Siles L *et al.* High rate of antibiotic resistance among pneumococci carried by healthy children in the Eastern part of the Democratic Republic of the Congo. *BMC Pediatrics*. 2018 November 19;18(1): 361. **Google Scholar**

Table 1: socio-demographic data and clinical characteristics of the children treated at the hospitals due to acute lower respiratory infection during 2010-2015

		Number of children (%) (N=2,007)
Hospital	CIRIRI	472 (23.5)
	NYANTENDE	682 (34.0)
	MITIMURHESA	590 (29.4)
	PANZI	263 (13.1)
	Total	2,007 (9.4)
Sex	Girl	960 (47.8)
	Boy	1,047 (52.2)
Age (months)	2-6	508 (25.3)
	7-12	622 (31.0)
	13-24	481 (24.0)
	25-36	190 (9.5)
	37-59	206 (10.3)
Symptoms	Cough or history of coughing	2,006 (100)
	Abnormal auscultation	2,007 (100)
	Fever or history of fever	2,007 (100)
	Rapid or difficult breathing	868 (43.2)
	Weakness or fatigue	1,487 (74.1)
	Diarrhoea/vomiting	117 (5.8)
	Other symptoms a	86 (4.3)
Nutritional Status	Malnutrition b	238 (11.9)
Congenital diseases c		30 (1.5)
HIV		25 (1.3)
ALRI	Non-severe ALRI	1,465 (73.0)
	Severe ALRI	542 (27.0)
Antibiotic used	Ampicillin and gentamicin	1,313 (65.4)
	Ceftriaxone and gentamicin	598 (29.8)
	Ciprofloxacin	70 (3.5)
	Chloramphenicol	26 (1.3)
Oxygen used	Nasal oxygen	228 (11.4)
Duration of hospital stay (days)	0-2	107 (5.3)
	3-7	1,012 (50.4)
	>8	888 (44.2)
Outcome	Pleural effusion as complication	21 (1.0)
	Improved and cured	1,908 (95.1)
	Death	99 (4.9)
	Death before 48 hours	66 (3.3%)
	Death after 48 hours	33 (1.7%)

a) Other symptoms: cutaneous-mucous pallor, jaundice, skin rash, seizures, loss of consciousness.
 b) Malnutrition: A Z-score cut-off point of <-2 SD to classify low weight-for-age. c) Congenital diseases: sickle cell diseases, congenital heart diseases, clinical Downs syndrome, clinical malformation of legs or arms.
 ALRI = acute lower respiratory infection

Table 2: socio-demographic characteristics of hospitalized children with ALRI during 2010-2015

		Cases with ALRI/N total inpatients (%) (N=21,478)
Hospital	CIRIRI	472/2,617 (18.0)
	NYANTENDE	682/5,981 (11.4)
	MITIMURHESA	590/7,387 (7.9)
	PANZI	263/5,493 (4.8)
	Total	2,007/21,478 (9.4)
Sex	Girls	960/9,693 (9.9)
	Boys	1,047/11,785 (8.9)
Age (months)	2-6	508/ 4,701 (10.8)
	7-12	622/4,519 (13.8)
	13-24	481/3,946 (12.2)
	25-36	190/2,539 (7.5)
	37-59	206/2,291 (9.0)

Table 3: morbidity and case fatalities of acute lower respiratory infections (ALRI) by year mean (annual average) both before (2010-2012) and after (2014-2015) start of PCV13 immunization

		Before PCV13 Annual average	After PCV13 Annual average		
		ALRI cases/N inpatients (%)	ALRI cases/N inpatients (%)	OR (CI=95%)	p-value
Hospital	CIRIRI	86/394 (21.8)	75/556 (13.5)	0.61 (0.44-0.86)	0.0049
	NYANTENDE	125/926 (13.5)	104/1,202 (8.7)	0.64 (0.48-0.84)	0.0015
	MITIMURHESA	83/694 (12.0)	123/2,033 (6.0)	0.50 (0.37-0.67)	<0.0001
	PANZI	43/747 (5.8)	46/1,114 (4.1)	0.71 (0.47-1.09)	0.126
	TOTAL	336/2,761 (12.2)	347/4,857 (7.1)	0.58 (0.50-0.68)	<0.0001
Sex	Girls	150/1,344 (11.2)	172/2,363 (7.3)	0.65 (0.51-0.82)	0.0003
	Boys	187/1,417 (13.2)	175/2,494 (7.0)	0.53 (0.42-0.66)	<0.0001
Age (months)	2-6	88/675 (13.0)	78/1,338 (5.8)	0.44 (0.32-0.61)	<0.0001
	7-12	113/659 (17.1)	99/1,272 (7.8)	0.45 (0.34-0.60)	<0.0001
	13-24	75/612 (12.3)	92/1,056 (8.7)	0.71 (0.51-0.97)	0.037
	25-36	31/472 (6.6)	34/562 (6.0)	0.92 (0.55-1.52)	0.74
	37-59	29/344 (8.4)	45/630 (7.1)	0.84 (0.52-1.37)	0.50
		ALRI cases (%) (N=336)	ALRI cases (%) (N=347)		
Symptoms	Cough or history of coughing	336 (100)	347 (100)	1.03(0.02-52.19)	0.98
	Abnormal auscultation	336 (100)	347 (100)	1.03(0.02-52.19)	0.98
	Fever or history of fever	336 (100)	347 (100)	1.03(0.02-52.19)	0.98
	Rapid or difficult breathing	154 (45.8)	123 (35.4)	0.68 (0.50-0.93)	0.016
	Weakness or fatigue	250 (74.4)	250 (72.0)	0.88 (0.63-1.24)	0.48
	Diarrhoea or vomiting	19 (5.7)	22 (6.3)	1.12 (0.59-2.12)	0.70
	Other symptoms a	18 (5.4)	10 (2.9)	0.52 (0.23-1.15)	0.10
Nutritional Status	Malnutrition b	35 (10.4)	48 (13.8)	1.38 (0.86-2.19)	0.17
Congenital diseases c		3 (0.9)	6 (1.7)	1.95 (0.48-7.87)	0.34
HIV		3 (0.9)	5 (1.4)	1.62 (0.38-6.82)	0.50
ALRI	Non-severe ALRI	234 (69.6)	283 (81.6)	1.92 (1.34-2.75)	0.0003
	Severe ALRI	103 (30.7)	64 (18.4)	0.51 (0.35-0.73)	0.0002
Antibiotic used	Ampicillin and gentamicin	232 (69.0)	219 (63.1)	0.76 (0.55-1.05)	0.10
	Ceftriaxone and gentamicin	88 (26.2)	114 (32.9)	1.46 (1.04-2.03)	0.025
	Ciprofloxacin	11 (3.3)	12 (3.5)	1.05 (0.46-2.43)	0.89
	Chloramphenicol	5 (1.5)	3 (0.9)	0.55 (0.13-2.43)	0.45
Oxygen used	Nasal oxygen	38 (11.3)	39 (11.2)	1.08 (0.67-1.76)	0.72
Duration of hospital stay (days)	0-2 days	16 (4.8)	21 (6.0)	1.28 (0.66-2.51)	0.45
	3-7 days	174 (51.8)	183 (52.7)	1.03 (0.76-1.40)	0.80
	>8 days	146 (43.5)	144 (41.5)	0.92 (0.68-1.25)	0.60
Outcome	Death	16 (4.8)	17 (4.9)	1.06 (0.52-2.13)	0.86
	Pleural effusion	6 (1.8)	1 (0.3)	0.15 (0.02-1.32)	0.08
	Improved and cured	320 (95.2)	330 (95.1)	0.97 (0.48-1.95)	0.94

Table 4: identified fatality risk factors among hospitalised children with acute lower respiratory infections (ALRI) (n=2,007) during the period between 2010-2015

Risk factors	Death	Univariable analysis		Multivariable Analysis	
		Unadjusted OR (CI=95%)	p-value	Adjusted OR (CI = 95%)	p-value
Age (months)	37-59	7/199	1		
	25-36	7/183	1.08 (0.37-3.16)	0.87	-
	13-24	18/463	1.10 (0.45-2.69)	0.82	-
	7-12	28/594	1.36 (0.58-3.16)	0.47	-
	2-6	39/469	2.36 (1.03-5.37)	0.04	-
Sex	Girls	47/913	1		
	Boys	52/995	1.01 (0.67-1.52)	0.94	-
Severe ALRI	No	10/1455	1		
	Yes	89/453	28.58 (14.74-55.42)	<0.0001	139.06 (86.94-145.8) <0.0001
Malnutrition a	No	48/1721	1		
	Yes	51/187	9.77 (6.41-14.91)	<0.0001	8.03 (3.18-20.28) <0.0001
Congenital diseases b	No	88/1889	1		
	Yes	11/19	12.42 (5.73-26.91)	<0.0001	9.85 (1.76-55.28) <0.0001
Rapid breathing c	No	28/1083	1		
	Yes	71/740	3.71 (2.37-5.80)	<0.0001	1.38 (0.38-4.94) 0.61
Fatigue	No	9/487	1		
	Yes	90/1237	3.93 (1.96-7.87)	0.0001	2.75 (0.63-11.92) 0.01




Figure 1: frequencies of acute lower respiratory infections (ALRIs) and fatal outcome by month in children 2-59 months of age treated due to ALRI at four different hospitals in the east of DR Congo between 2010 and 2015